CHF 4226

· Chiesi Farmaceutici S.p.A.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CHF 4226, covering 2017-04-11 to 2019-11-06. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

See pricing